Key result
The cardiac ryanodine receptor (RyR2), but not sarcoplasmic reticulum Ca2+-ATPase, is a major determinant of Ca2+ alternans in intact mouse hearts and an important therapeutic target.
Why the study?
Is the cardiac ryanodine receptor or sarcoplasmic reticulum Ca2+-ATPase a major determinant of Ca2+ alternans in intact mouse hearts?
Is the cardiac ryanodine receptor or sarcoplasmic reticulum Ca2+-ATPase a major determinant of Ca2+ alternans in intact mouse hearts?
RyR2 is identified as a major determinant of Ca2+ alternans in intact mouse hearts, highlighting it as an important therapeutic target.
RyR2 targeting may mitigate Ca2+ alternans; leaves open therapeutic potential pending human validation.
alternans in intact working hearts, making RyR2 an important therapeutic target for cardiac alternans.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2018) studied this question. The cardiac ryanodine receptor (RyR2), but not sarcoplasmic reticulum Ca2+-ATPase, is a major determinant of Ca2+ alternans in intact mouse hearts and an important therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: